Top

Supportive Care in Cancer

Published in:

01-02-2015 | Letter to the Editor

Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience

Authors: Claudio Cerchione, Lucio Catalano, Anna Emanuele Pareto, Marco Picardi, Fabrizio Pane

Published in: Supportive Care in Cancer | Issue 2/2015

Excerpt

Dear Editor, …

Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100:228–237PubMedCrossRef

Pettengell R, Schwenkglenks M, Leonard R et al (2008) Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 16:1299–1309PubMedCrossRef

United States Department of Health & Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Published: May 28, 2009 (v4.03: June 14, 2010)

Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205PubMedCrossRef

National Comprehensive Cancer Network (NCCN), Inc. Clinical Practice Guidelines in Oncology: Myeloid Growth Factors Version 1.2012. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive. Accessed 1 Aug 2012

Amgen, Inc.(2011) Neulasta (pegfilgrastim) [prescribing information]. Thousand Oaks, CA: Amgen, Inc. http://pi.amgen.com/united_states/neulasta/neulasta_pi_hcp_english.pdf. Accessed Aug 28 2011

Green MD, Koelbl H, Baselga J et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29–35PubMedCrossRef

Balducci L et al (2007) Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 12:1416–1424PubMedCrossRef

Ludwig H et al. (2014) European perspective on multiple myeloma treatment strategies in 2014. Oncol

10.

Cömert M et al (2013) Quality of life and supportive care in multiple myeloma. Turk J Haematol 30(3):234–246PubMedCentralPubMedCrossRef

Title: Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience
Authors: Claudio Cerchione
Lucio Catalano
Anna Emanuele Pareto
Marco Picardi
Fabrizio Pane
Publication date: 01-02-2015
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 2/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-014-2490-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2015

Adolescents and young adult cancer survivors: exercise habits, quality of life and physical activity preferences

Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors

Changes in sleep and fatigue in newly treated pediatric oncology patients

Peripherally inserted central catheters in non-hospitalized cancer patients: 5-year results of a prospective study

A randomized controlled clinical trial of formalin for treatment of chronic hemorrhagic radiation proctopathy in cervical carcinoma patients

Miconazole mucoadhesive buccal tablet in high-dose therapy with autologous stem cell transplantation (HDT/ASCT)-induced mucositis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer